These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 22897584)

  • 1. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.
    Varmavuo V; Mäntymaa P; Silvennoinen R; Nousiainen T; Kuittinen T; Jantunen E
    Transfusion; 2013 May; 53(5):1024-32. PubMed ID: 22897584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood graft composition after plerixafor injection in patients with NHL.
    Varmavuo V; Mäntymaa P; Nousiainen T; Valonen P; Kuittinen T; Jantunen E
    Eur J Haematol; 2012 Aug; 89(2):128-35. PubMed ID: 22536949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.
    Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Säily M; Sankelo M; Terävä V; Putkonen M; Kuittinen T; Pelkonen J; Mäntymaa P; Remes K; Varmavuo V; Jantunen E
    Transfusion; 2016 Jun; 56(6):1394-401. PubMed ID: 27041692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
    Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A
    Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
    Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
    J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
    Hundemer M; Engelhardt M; Bruckner T; Kraeker S; Schmitt A; Sauer S; Neben K; Witzens-Harig M; Goldschmidt H; Ho AD; Wuchter P
    J Clin Apher; 2014 Dec; 29(6):299-304. PubMed ID: 24771277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.
    Jantunen E; Varmavuo V; Valtola J
    Expert Rev Hematol; 2016 Aug; 9(8):723-32. PubMed ID: 27355397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
    Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN
    Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma.
    Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP
    Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor.
    Uchida N; Bonifacino A; Krouse AE; Metzger ME; Csako G; Lee-Stroka A; Fasano RM; Leitman SF; Mattapallil JJ; Hsieh MM; Tisdale JF; Donahue RE
    Exp Hematol; 2011 Jul; 39(7):795-805. PubMed ID: 21549175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
    Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
    Farina L; Spina F; Guidetti A; Longoni P; Ravagnani F; Dodero A; Montefusco V; Carlo-Stella C; Corradini P
    Leuk Lymphoma; 2014 Feb; 55(2):331-6. PubMed ID: 23656194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
    Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA
    Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
    Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
    J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
    Holmberg LA; Linenberger M; Connelly-Smith L
    Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.